OncBioMune Announces Compelling Pre-clinical Data for its CD71-targeted Chemotherapy, PGT, in Models of Lung, Pancreatic and Ovarian Cancers
July 15, 2019 09:42 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., July 15, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Announces Initial In Vitro Proof-of-Concept Data for PGT in a Multi-Drug Resistant Ovarian Cancer Model
May 30, 2019 09:08 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., May 30, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Announces Agreement with CATO BioVentures as a Strategic Investor in Support of CD71-Targeted Therapy for Refractory Cancers
May 01, 2019 09:28 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., May 01, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment
March 19, 2019 08:30 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 19, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers
February 28, 2019 08:29 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Feb. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
Dr. Mitesh Borad Joins OncBioMune Scientific Advisory Board
January 28, 2019 08:54 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer
January 09, 2019 08:28 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Jan. 09, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer
December 07, 2018 09:00 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Dec. 07, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Developments and Corporate Milestones
November 08, 2018 09:08 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Nov. 08, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune CEO Dr. Jonathan Head Speaking at 2018 Global Summit on Genitourinary Malignancies
October 31, 2018 09:00 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Oct. 31, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...